Biodesix Inc
NASDAQ:BDSX
Biodesix Inc
Other Items
Biodesix Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biodesix Inc
NASDAQ:BDSX
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Other Items
-$104m
|
CAGR 3-Years
9%
|
CAGR 5-Years
22%
|
CAGR 10-Years
0%
|
|
|
CVS Health Corp
NYSE:CVS
|
Other Items
-$3B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
12%
|
|
|
Cigna Corp
NYSE:CI
|
Other Items
-$3.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-10%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Other Items
-$759.5m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
15%
|
|
|
Guardant Health Inc
NASDAQ:GH
|
Other Items
-$578.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
Biodesix Inc
Glance View
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.
